—

Vertex Pharmaceuticals Inc (VRTX) — Technical state

As of 2026-11-13 — re-computed nightly across the coverage universe. Closelooknet diary readings, not advice.

The Closelooknet read

  • Closelooknet score: 55 out of 100 (momentum 81 · quality 82 · valuation 24), as of 2026-11-17.
  • Signal: -0.7% at the close — Holding 5.3% off its 52-week high. (as of 2026-11-13)
  • Trend: Vertex Pharmaceuticals Inc trades 3.1% above its 50-day and 11.4% above its 200-day moving average. (as of 2026-11-13)
  • Index seat: HALO Growth 100

Vertex Pharmaceuticals is a biotechnology company that sells drugs for cystic fibrosis, a lung and digestive disease caused by a faulty gene, including its main products Trikafta and Kaftrio. It also markets Casgevy, a gene-edited therapy for sickle cell disease and transfusion-dependent beta thalassemia, and Journavx for acute pain.

The full read — the desk's view, the earnings record, peers and the company snapshot — is on the VRTX overview. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.

-0.7% at the close

Holding 5.3% off its 52-week high.

The moving-average stack

FAQ · from the current data · as of 2026-11-13

Quick answers

What is the current Closelooknet signal on VRTX?

-0.7% at the close — Holding 5.3% off its 52-week high. As of 2026-11-13; the signal board re-computes across the coverage universe nightly. A research diary reading, not advice.

Is VRTX above its 50-day and 200-day moving averages?

As of 2026-11-13, Vertex Pharmaceuticals Inc trades +3.1% above its 50-day and +11.4% above its 200-day average, with the 20-day +0.5% away.

How far is VRTX from its 52-week high?

5.3% below the 52-week high and 33.8% above the 52-week low, as of 2026-11-13.

Mentioned on Closelooknet

Where VRTX appears in the diary — 1 piece, newest first. Every link is our own writing.

Dailies

Related in the Closelooknet universe

same Closelooknet index seat first, then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.